Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Monocarboxylate Transporters>>AZD 3965

AZD 3965 Sale

目录号 : GC11010

A selective inhibitor of MCT1

AZD 3965 Chemical Structure

Cas No.:1448671-31-5

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥1,190.00
现货
2mg
¥693.00
现货
5mg
¥1,050.00
现货
10mg
¥1,680.00
现货
50mg
¥5,460.00
现货
100mg
¥9,100.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Kinase experiment:

Cells are plated overnight and treated with 100 nM AZD3965 or vehicle for 24 hours. The cells are then washed, once in PBS and twice with lysis buffer (50 mM Mops, 100 mM KCl, 5 mM MgCl2, 1 mM EDTA, 0.1 mM DTT, 1 mM PMSF supplemented with 1× mini complete protease inhibitor cocktail tablets. The cells are harvested by scraping and centrifugation, and the pellet snap frozen without buffer in liquid nitrogen. Frozen aliquots of cells are thawed on ice and re-suspended in lysis buffer. Cells are lysed by 3 rounds of freezing in liquid nitrogen and thawing at 37°C for 2 minutes each. Lysates are subsequently centrifuged (13000 g, 10min, 4°C) until clear and then stored on ice. Enzyme activity in the cell lysates is determined using a micro-plate reader to measure either production or depletion of NADH/NADPH, through its absorbance at 340/10 nm, occurring as a result of direct or coupled enzyme reactions. The 96 well plates used for the assays are pre-heated to 37°C for 10 minutes prior to starting reactions, initiated by the addition of 5 μL cell lysate to 95 μL of reaction buffer (50 mM Mops pH 7.4, 100 mM KCl, 5 mM free magnesium). The standard reaction buffer is supplemented to assay the kinetics of the different enzymes. Absorbance values for controls are subtracted from absorbance of corresponding reactions. Graphpad prism 6 is used to plot V0 values against substrate concentration and determine Vmax and Km values. The Vmax is then normalised to the protein concentration in the cell lysate[1].

Animal experiment:

Mice[2] COR-L103 xenografts are grown by subcutaneous injection of 5×106 cells in 0.2 mL of 1:1 serum-free RPMI:Matrigel into the mid-dorsal flank of 8 to 14-week-old male NOD scid gamma mice. Mice are housed in individually vented caging systems in a 12-hour light/12-hour dark environment and maintained at uniform temperature and humidity. Tumor size is measured twice a week using calipers and the volume calculated as tumor length×tumor width2/2. 30 days after implantation, mice bearing tumors between 150 and 250mm3 are randomized into two groups of six and treated with 100 mg/kg BID AZD3965 in 0.5% hydroxypropyl methyl cellulose, 0.1% tween 80 or vehicle only by oral gavage for 21 days. Measurements are continued 3 times a week for the duration of drug treatment to assess tumor growth kinetics. At sacrifice tumors are collected to determine intra-tumor lactate concentration.

References:

[1]. Bola BM, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014 Dec;13(12):2805-16.
[2]. Polanski R, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014 Feb 15;20(4):926-37.

产品描述

Ki = 1.6 nM for MCT1

AZD 3965 is a potent inhibitor of monocarboxylate transporter 1 (MCT1).

Inhibition of monocarboxylate transporter 1 (MCT1) is currently considered as a promosing therapeutic way to block lactate shuttling in tumor cells lacking monocarboxylate transporter 4.

In vitro: Previous study found that the in-vitro AZD3965 sensitivity varied and was highest in hypoxia. To further support that AZD3965 targeted MCT1, NCIH1048 cells were engineered to inducibly overexpress MCT1. It was found that when MCT1 was overexpressed, the EC50 of AZD 3965 against NCI-H1048 was increased from 0.14 to 10.5 nM, which was consistent with AZD3965 acting through MCT1 inhibition [1].

In vivo: COR-L103 xenograft studies were conducted to test whether the in-vitro effect of AZD3965 could be recapitulated in vivo. COR-L103 tumor-bearing mice were treated with AZD3965 at 100 mg/kg BID for 21 days. The pharmacokinetic analyses showed that AZD3965 at 100 mg/kg BID led to free concentrations of AZD3965 predicted to inhibit lactate transport. Moreover, AZD3965 treatment was able to reduce the growth of CORL103 tumors significantly, though tumor regression was not observed, which was consistent with AZD3965 only targeting the hypoxic fraction of the tumor [1].

Clinical trial: A phase I trial of AZD3965 in patients with advanced cancer is currently recruiting participants [2].

References:
[1] Polanski, R. ,Hodgkinson, C.L.,Fusi, A., et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin.Cancer.Res 20(4), (2014).
[2] https://clinicaltrials. gov/ct2/show/NCT01791595 term=AZD+3965&rank=1

MCT1 的 Ki = 1.6 nM

AZD 3965 是单羧酸转运蛋白 1 (MCT1) 的有效抑制剂。

抑制单羧酸转运蛋白 1 (MCT1) 目前被认为是一种促进缺乏单羧酸转运蛋白 4 的肿瘤细胞中乳酸穿梭的治疗方法。

体外:先前的研究发现体外 AZD3965 敏感性不同,在缺氧条件下最高。为了进一步支持 AZD3965 以 MCT1 为靶点,NCIH1048 细胞被设计为诱导性过表达 MCT1。结果发现,当 MCT1 过表达时,AZD 3965 对 NCI-H1048 的 EC50 从 0.14 增加到 10.5 nM,这与 AZD3965 通过 MCT1 抑制作用一致 [1]。

体内:COR -L103 异种移植研究是为了测试 AZD3965 的体外作用是否可以在体内重现。用 100 mg/kg BID 的 AZD3965 处理 COR-L103 荷瘤小鼠 21 天。药代动力学分析表明,100 mg/kg BID 的 AZD3965 导致预测抑制乳酸转运的 AZD3965 游离浓度。此外,AZD3965 治疗能够显着减少 CORL103 肿瘤的生长,但未观察到肿瘤消退,这与 AZD3965 仅靶向肿瘤缺氧部分一致 [1]。

临床试验:AZD3965在晚期癌症患者中的I期试验目前正在招募参与者[2]。

Chemical Properties

Cas No. 1448671-31-5 SDF
化学名 5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
Canonical SMILES CC(C)N(C(N1C)=O)C2=C(C(C(N3C[C@](C)(O)CO3)=O)=C(CC4=C(C)NN=C4C(F)(F)F)S2)C1=O
分子式 C21H24F3N5O5S 分子量 515.5
溶解度 ≥ 51.6mg/mL in EtOH, ≥ 51.5mg/mL in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.9399 mL 9.6993 mL 19.3986 mL
5 mM 0.388 mL 1.9399 mL 3.8797 mL
10 mM 0.194 mL 0.9699 mL 1.9399 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置